|
StatusThe thesis was presented on the 14 December, 2010Approved by NCAA on the 24 February, 2011 Abstract![]() |
Thesis structure: introduction, 6 chapters, conclusions and recommendations, bibliography sources includes 200 sources. The paper contains 112 typed pages, 53 tables, 20 schemes. The results obtained have been published in 18 scientific works.
Study domain: diagnosis and treatment of the Breast Cancer.
Goal of the study is estimation of effectiveness of the Breast Cancer stage I treatment depending on divers factors and selection of decisive prognosis factors for the purpose of treatment individualization.
Objectives of the study. Analysis of the informative value of diagnostic methods of Breast Cancer stage I, analysis of treatment results. Selection of decisive factors in Breast Cancer stage I treatment. Analysis of immunological and hormonal status of Breast Cancer stage I patients depending on pathologies and level of expression of molecular markers - RE, RP and HER2/neu.
Scientific innovation. Decisive prognosis factors in treatment of Breast Cancer stage I have been determined. Based on the prognosis factors, optimal schemes and their order of application of combined or complex treatment have been recommended; level and type of immunological and hormonal deviations in Breast Cancer stage I have been determined; the expression of molecular markers HER2/neu and RE and RP has been established.
The theoretical significance of the work. Knowledge supplement in determined of decisive prognosis factors in treatment of Breast Cancer stage I, level and type of immunological and hormonal deviations, the expression of molecular markers HER2/ neu and RE and RP.
Practical value of the study. The informative value of diagnostic methods - USG, MG and cytology in Breast Cancer stage I, selection of decisive factors in clinical evolution allowed elaborating an optimal scheme for medical investigation and treatment of Breast Cancer patients stage I. Establishment of the degree of immunological depression and hormonal deviations in Breast Cancer stage I allows to recommend treatment of correction. Evaluation of the level of expression of HER2/neu in accordance with the level of expression of RE, RP contributed to individualization of chemotherapy and hormonal treatment. Selection of optimal schemes of treatment will contribute to reduction of mortality from early forms of Breast Cancer.
The obtained results are implementedin curative activity of treatment of the Breast
Cancer stage I in the departments of OI , were included in Clinic National Protocol
„Breast Cancer”.